期刊
PHARMACEUTICS
卷 14, 期 8, 页码 -出版社
MDPI
DOI: 10.3390/pharmaceutics14081671
关键词
proteins; adjuvants; vaccines; protein-based adjuvants; Toll-like receptors; C-type lectin receptors; innate immune response; adaptive immune response
资金
- CONICYT-CHILE FONDECYT Regular Grant [1201600]
- National Commission for Scientific and Technological Research (CONICYT), Chile
- ANID [21200880, 21210946]
This review article discusses the potential role of protein-based adjuvants in vaccine development. Despite their structural differences, all protein-based adjuvants have significant immunostimulatory properties and interact with innate immune receptors, enhancing the effectiveness of vaccines. Therefore, protein-based adjuvants are expected to play an important role in the development of vaccines against different types of pathogens.
New-generation vaccines, formulated with subunits or nucleic acids, are less immunogenic than classical vaccines formulated with live-attenuated or inactivated pathogens. This difference has led to an intensified search for additional potent vaccine adjuvants that meet safety and efficacy criteria and confer long-term protection. This review provides an overview of protein-based adjuvants (PBAs) obtained from different organisms, including bacteria, mollusks, plants, and humans. Notably, despite structural differences, all PBAs show significant immunostimulatory properties, eliciting B-cell- and T-cell-mediated immune responses to administered antigens, providing advantages over many currently adopted adjuvant approaches. Furthermore, PBAs are natural biocompatible and biodegradable substances that induce minimal reactogenicity and toxicity and interact with innate immune receptors, enhancing their endocytosis and modulating subsequent adaptive immune responses. We propose that PBAs can contribute to the development of vaccines against complex pathogens, including intracellular pathogens such as Mycobacterium tuberculosis, those with complex life cycles such as Plasmodium falciparum, those that induce host immune dysfunction such as HIV, those that target immunocompromised individuals such as fungi, those with a latent disease phase such as Herpes, those that are antigenically variable such as SARS-CoV-2 and those that undergo continuous evolution, to reduce the likelihood of outbreaks.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据